SecBot SecBot

NVS

NOVARTIS AG
NYSE· Pharmaceutical Preparations· Inc. V8· CIK 0001114448 Biotech & Drug Discovery
$159.94 −0.56 (−0.35%)
Nov 16 4:00 PM ET · prev $160.50
Market cap
$305.8B
Mega cap
Consensus
Buy
44% Buy or better · 34 analysts
Median target
$158.50
−1% · range $130.00–185.00
1 year
+21.6%
from $131.55 · Nov 17
30 days
+6.5%
from $150.20
52-week range
$124.36–168.62
−5% from high · low Nov 20
Avg volume 20D
2.17M
shares / day
Short interest
4.52M
≈0.2% of shares · −19.1%
Days to cover
1.9
at average volume
New fund stakes
5
Q2 2026 13F · 1 exit
Filing reports
16
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 2 bearish · 1 bullish · 2 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 23 added (5 new), 21 trimmed or exited. Largest new: Holocene Advisors $162.6M, Millennium Management $118.8M.

  • AnalystsBULLISH

    15 of 34 rate it Buy or better. Median target $158.50 (−1%).

  • EstimatesRISING

    Current-quarter EPS estimate $2.103 → $2.231 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −19.1% to 4.52M shares. 1.9 days to cover, ≈0.2% of shares.

  • TrendUPTREND

    7% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q2 2026
5
new positions
1
exit
$408.0M
in new stakes
FundMoveSharesValue
GOLDMAN SACHS GROUP INCTRIM2,980,168$467.1M
JPMORGAN CHASE & COADD2,264,447$356.9M
WCM INVESTMENT MANAGEMENT, LLCADD1,904,349$300.1M
UBS Group AGTRIM1,184,422$185.6M
Holocene Advisors, LPNEW1,037,332$162.6M
RENAISSANCE TECHNOLOGIES LLCTRIM788,033$123.5M
DODGE & COXNEAR_EXIT759,373$119.0M
MILLENNIUM MANAGEMENT LLCNEW758,029$118.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

34 analysts
Buy 44% rate it Buy or better
Strong Buy6Buy9Hold15Sell4Strong Sell0
12-month targets · 10 analysts

Price is inside the target range. Median implies −1%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 30, 2026Deutsche Bank
DOWNGRADE
DOWNGRADESell
Sep 10, 2026HSBC
UPGRADE
UPGRADEHold

Washington

Corporate Lobbying

89 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Earnings setup

Estimates
$2.23
EPS estimate, this quarter
+6%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$2.23$2.19–$2.31+6.1%$14.8B
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 12, 2026 SEC
Novartis AG, through its subsidiary Novartis Capital Corporation, issued $5.5 billion aggregate principal amount of…
6-K · Impact 3/10
Nov 10, 2026 Event
HSR Early Termination: Novartis AG; Bo Ying
The FTC granted early termination of the HSR Act waiting period for a transaction involving Novartis
Nov 10, 2026 SEC
The PTAB granted institution of IPR2026-00260, allowing Amneal and Kashiv to challenge claims of Novartis's patent…
PTAB-TRIAL · Impact 3/10
Oct 28, 2026 SEC
Victor Bulto Carulla, an officer of Novartis AG, filed a Form 144 notice of intent to sell 6,000 American Depositary…
144 · Impact 2/10
Aug 19, 2026 Event
Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34
Class II: Failed Dissolution Specifications
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC · TRIM
2,980,168 shares ($467.1M)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO · ADD
2,264,447 shares ($356.9M)

Short side

FINRA· Oct 30, 2026
4,515,670
shares short
-19.1%
vs prior settlement
1.9
days to cover
≈0.2%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
21 drugs tracked · Drug pipeline →
Recent
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 16, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Nov 10, 2026
Enforcement
HSR Early Termination: Novartis AG; Bo Ying
The FTC granted early termination of the HSR Act waiting period for a transaction involving Novartis AG; Bo Ying.
Nov 10, 2026
Ptab trial
PTAB IPR2026-00260: Trial instituted, U.S. Patent 12030959 (Genentech Inc. v. Amneal Pharmaceuticals, Inc.)
Patent: ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
Reddit
Recent posts
All social signals and their track records

SecBot reports

16 filings · 1 bullish · 5 bearish · 2 mixed · 8 neutral
All NVS filing & press-release reports (16)